cis-decahydroquinoxaline | 118948-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: cis-decahydroquinoxaline
• 英文别名: cis-perhydroquinoxaline；cis-Decahydro-chinoxalin；(4aR,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline
• CAS: 118948-26-8
• 化学式: C₈H₁₆N₂
• 分子量: 140.228
• InChiKey: MDEXMBGPIZUUBI-OCAPTIKFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-decahydroquinoxaline 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 异戊醇 、 二氯甲烷 为溶剂， 反应 75.0h， 生成 [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-cis-perhydro-1-quinoxalinyl](phenyl)methanone
  参考文献：
  名称：

  Searching for cyclazosin analogues as α1B-adrenoceptor antagonists

  摘要：

  A series of quinazoline derivatives, 2-20, structurally related to the racemic alpha(1)-adrenoceptor antagonist cyclazosin (1), were synthesized and evaluated for their functional antagonism at alpha(1)- and alpha(2)-adrenoceptors and for their binding affinity at human cloned alpha(1a)-, alpha(1b)- and alpha(1d)-adrenoceptor subtypes. They displayed, like 1, preferential antagonism and selectivity for alpha(1) versus alpha(2)-adrenoceptors. Compounds 10, 13, and 18 showed high potency at alpha(1)-adrenoceptors similar to that of 1 (pK(B) values 8.47-8.89 versus 8.67), whereas 13 and 15 were endowed with the highest alpha(1)-adrenoceptor selectivity, only 3- to 4-fold lower than that of 1. In binding experiments, all of the compounds displayed an affinity practically similar to that found for 1, with the exception of 19 and 20 that were definitely less potent. The s-triazine analogue 18 was the most potent of the series with pK(i) values of 10.15 (alpha(1a)), 10.22 (alpha(1b)) and 10.40 (alpha(1d)), resulting 77-fold more potent than 1 at alpha(1a)-adrenoceptors. In addition, the majority of compounds, like prototype 1, showed the same trend of preferential affinity for alpha(1d)- and alpha(1b)-adrenoceptors that alpha(1a)-subtype. In conclusion, we identified compounds 2-5, 10, 12 and 13, bearing either an aliphatic- or an arylalkyl- or aryloxyalkyl-acyl function, with an interesting subtype-selectivity profile, which makes them suitable candidates for their resolution as enantiomers structurally related to (+)-cyclazosin.

  DOI：

  10.1016/s0014-827x(02)00025-3
• 作为产物：
  描述：

  1,2,3,4-四氢喹喔啉 在 [Rh(cod)(CI)(CAAC^Cy)] 、 氢气 作用下， 以 2,2,2-三氟乙醇 为溶剂， 50.0 ℃ 、5.0 MPa 条件下， 反应 24.0h， 以98%的产率得到
  参考文献：
  名称：

  铑（CAAC）催化苯并稠合 N-杂环芳烃加氢生成全顺式结构的饱和结构单元

  摘要：

  饱和碳环和杂环结构单元可以很容易地通过芳族碳环和杂环的氢化获得。尽管已经建立了多种方法来完成简单芳烃的这种转化，但对芳族N-杂环的氢化研究较少。我们在此报告了一种非对映选择性芳烃氢化，该氢化作用应用于一系列苯并稠合的N-杂环。在铑络合物Cy (CAAC)Rh(cod)Cl的存在下，通过氢化得到总共 48 个饱和杂环，产率为 72-98%，具有中到高的非对映选择性，氢原子呈全顺式。安排。对官能团的高耐受性能够形成有价值的饱和产物，这为进一步衍生化提供了起点。

  DOI：

  10.1002/adsc.202200582

文献信息

• [EN] PERHYDROQUINOXALINE DERIVATIVES USEFUL AS ANALGESICS<br/>[FR] DÉRIVÉS DE PÉRHYDROQUINOXALINE UTILES EN TANT QU'ANALGÉSIQUES
  申请人：WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR

  公开号：WO2014184355A1

  公开（公告）日：2014-11-20

  The present invention relates to perhydroquinoxaline compounds according to the general formula (1), their use as a medicament, in particular as analgesic, antipruritic and antiinflammatory agents, and their preparation.

  本发明涉及按照通式（1）的过氧化喹啉化合物，其作为药物的用途，特别是作为镇痛、止痒和抗炎药剂，以及它们的制备。
• [EN] PEPTIDE DEFORMYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PEPTIDE DÉFORMYLASE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009061879A1

  公开（公告）日：2009-05-14

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟甲酰胺衍生物，含有它们的组合物，以及这些化合物在抑制细菌肽变形酶（PDF）活性和治疗细菌感染中的用途。具体而言，该发明涉及式（I）的化合物，其中R1、R2和R3在此有定义，并且其药用盐。本发明的这些化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
  申请人：Recordati S.A.

  公开号：US20020161009A1

  公开（公告）日：2002-10-31

  Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the &agr; 1B -adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

  本文描述了选择性&agr;1B-肾上腺素受体拮抗剂的使用，以治疗男性或女性性功能障碍，并包含它们的药物组合物作为有助于性行为的化合物，同时避免由于急性低血压而引起的过度副作用。
• Use of selective antagonists of the α1B-adrenergic receptor for improvement of sexual dysfunction
  申请人：Leonardi Amedeo

  公开号：US06953800B2

  公开（公告）日：2005-10-11

  Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the α 1B -adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.

  本发明描述了使用选择性α1B-肾上腺素能受体拮抗剂及含有它们的制药组合物来治疗男性或女性性功能障碍，这些化合物有助于性行为的进行，同时避免由急性低血压引起的过度副作用。
• Piperazines as P2X7 antagonists
  申请人：Betschmann Patrick

  公开号：US20080076924A1

  公开（公告）日：2008-03-27

  Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药，其中取代基如本文所定义，这些化合物可用作治疗剂。